Brief communication

Hepatitis B virus infection among institutionalized mentally ill patients in Brazil

Tatiane Cinquini Moraes, Fabíola Souza Fiaccadori, Menira Souza, Tâmerra Nunes Vieira Almeida, Marielton dos Passos Cunha, Ítalo de Araújo Castro, Divina das Dôres de Paula Cardoso*

Laboratório de Virologia Humana, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, GO, Brazil

ARTICLE INFO

Article history:
Received 4 May 2015
Accepted 12 July 2015
Available online 9 September 2015

Keywords:
Hepatitis B virus
Occult infection
Prevalence
Mental illness

ABSTRACT

Objectives: The main objective was to evaluate HBV infection and occult HBV infection (OBI) cases in mentally ill patients based on serological and molecular profiles.

Material and methods: Serum samples of 333 long-stay mentally ill patients were tested for the prevalence of HBV markers by serological (ELISA) and molecular (PCR) assays. The PCR products were sequenced to determine viral genotypes.

Results: It was observed a global prevalence of 12.9% (43/333) for HBV infection markers, considering HBsAg and/or anti-HBc positivity. Fourteen samples tested positive for anti-HBs alone. All samples positive (n = 57) for any HBV serological markers were tested for HBV-DNA and six were positive: HBsAg/anti-HBc (n = 1), anti-HBc/anti-HBs (n = 1), anti-HBs alone (n = 1), and anti-HBc alone (n = 3). The rate of OBI was 9.2% (5/54) from samples that were anti-HBc and/or anti-HBs positive. All sequenced samples were characterized as genotype A.

Conclusion: The high rate of HBV infections found in this study suggests the possibility of HBV transmission due to risk factors displayed by some patients, and highlights the importance of vaccination of susceptible patients and the staff of that institution.

© 2015 Elsevier Editora Ltda. All rights reserved.

Introduction

Hepatitis B virus (HBV) infection is a global public health issue. It is estimated that nearly two billion people worldwide have serological evidence of past or present HBV infection, whereas more than 240 million people, who are chronically infected, are at high risk of death from liver complications such as cirrhosis and hepatocellular carcinoma (HCC). According to the World Health Organization (WHO), more than 780 thousand people die every year as a consequence of acute or chronic HBV infection.1,2

The natural course of HBV infection is determined by the interactions between the host and the virus. Traditionally, clearance of HBV surface antigen (HBsAg) followed by positivity for anti-HBs is considered as infection recovery. Chronic
HBV infection is characterized by the persistence of HBsAg. Therefore, HBsAg and anti-HBc total represent viral exposure markers while anti-HBs is a surrogate for immunity against HBV.\textsuperscript{3,4} Additionally, the use of molecular biology techniques in the diagnosis of hepatitis B has allowed the identification of occult HBV infection (OBI) by detection of viral DNA that may or may not be present in the serum of HBsAg-negative individuals.\textsuperscript{5,6}

The clinical importance of OBI is that it constitutes a possible source of viral transmission. It has also been associated with the risk of disease reactivation during immunosuppression, and with progression to cirrhosis and/or HCC, since viral activity may determine a continuous inflammatory condition.\textsuperscript{7}

OBI has been observed in the general population\textsuperscript{8} as well as in distinct groups such as blood donors,\textsuperscript{9} transplant recipients,\textsuperscript{10} and in HIV-infected individuals.\textsuperscript{11} Mentally ill patients are also at risk for HBV infection, especially because of their peculiar behavior.\textsuperscript{12,13} To our knowledge data on HBV occurrence among these patients are limited, and data on the literature have focused on prevalence of HBV infection.\textsuperscript{14-19}

This study shows data on the serological and molecular profiles of HBV infection and OBI among long-stay mentally ill patients in a care center from Brazil.

**Material and methods**

**Study population**

A total of 333 blood samples from the same number of mentally ill patients, including 121 males and 212 females, were collected between July 2011 and January 2012. The age of the study patients varied from five to 106 years old: 78.7% of patients were in the range 11–60; 3.0% had up to 10 years, and 18.3% were older than 60 years. Of all patients 68.8% had more than 10 years of stay time in the institution and only 15 had evidence of vaccination against HBV. These patients were institutionalized in a care center in the state of Goiás, Brazil, where they received multidisciplinary care on the prevention, treatment, basic hygiene, and nutrition due to their partial or total dependence imposed by their disorders (physical, psychiatric, neurological).

A written consent was obtained from the day care center legal authority. The study was approved by the Ethics Committee of the Universidade Federal de Goiás (Protocol 182/11).

**Detection of serological markers**

All serum samples were tested by ELISA for the presence of anti-HBc (HEPANOSTIKA anti-HBc Uni-Form, bioMérieux, France), anti-HBs (ANTl-SURASE B-96 (TMB) (General Biologicals Corporation, Taiwan)), following the manufacturer’s instructions. For HBsAg, two commercial EIA kits were used: SURASE B-96 (General Biological Corporation, Taiwan) and “HBsAg one” (DIA.PRO, Diagnostic Bioprobes SRL, Italy), both with high sensitivity (100%) and specificity (99.5%), according to the manufacturers.

**HBV-DNA detection**

Serum samples that were positive for any of the HBV serological markers were submitted to DNA extraction using phenol/chloroform\textsuperscript{20} and subjected to a semi-nested PCR amplification of the preS2/S genomic region. The test has sensitivity to detect three DNA molecules per assay, as previous described.\textsuperscript{21} The first round of amplification was performed using sense primer PS1 (nt 2826–2845) and two antisense primers S2 (nt 819–841) and S22 (nt 819–841). For second round, sense primer PS1 and antisense primer SR (nt 685–704) were used, generating a 1099 fragment base pairs. To avoid cross-contamination, all procedures were performed in different PCR cabinets, with UV light decontamination before and after each step. Samples with distinct serological profile were tested separately, for each reaction and a negative control was included. In order to confirm the DNA-HBV positive samples, all procedures were repeated. A second blood sample was also obtained from each positive patient and re-tested.

**Genotyping**

The PCR products were sequenced as previously described,\textsuperscript{22} using the second-round primers and the ABI Prism Big Dye Terminator 3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA). After purification using QiAquick PCR Purification Kit (Qiagen, Freiburg, Germany), samples were denatured and directly sequenced using an automated sequencer (ABI 3130 Genetic Analyzer – Applied Biosystems, Foster City, CA). The quality of each electropherogram was evaluated using Phred software,\textsuperscript{23} and the sequences were aligned by ClustalX software.\textsuperscript{24} The genotypes were identified by phylogenetic reconstructions using reference sequences from each HBV genotype obtained from GenBank, and the tree was generated using the neighbor-joining algorithm method.\textsuperscript{25} Genetic distances were determined by the Kimura-2-parameters method\textsuperscript{26} using the software MEGA v.5.0.\textsuperscript{27}

**Results**

Out of 333 samples, 57 were positive for at least one HBV serological marker, which included two samples HBsAg positive alone, one HBsAg/anti-HBc, 26 anti-HBs/anti-HBc, 14 anti-HBc alone, and 14 anti-HBs alone (Table 1). Considering the exposure markers (HBsAg and/or anti-HBc) a global prevalence of HBV infection was 12.9% (43/333).

Fifty-seven samples were screened for HBV DNA and six of them were positive, with distinct serological profiles: HBsAg/anti-HBc (n = 1), anti-HBc/anti-HBs (n = 1), anti-HBs alone (n = 1) and anti-HBc alone (n = 3). Only samples positive for anti-HBc and/or anti-HBs were considered OBI, and a rate of 9.2% (5/54) was observed.

Nucleotide sequencing was performed successfully in all DNA-HBV positive samples. Sequences with 511bp of the pre S2/S partial region (nt113–623) were considered for the comparative analysis, which showed identities values varying from 98 to 99% in relation to the Brazilian isolate US5222, and all of them were characterized as genotype A (GenBank accession numbers KJ434163–KJ434168) (Fig. 1).
Table 1 – HBV serological markers in 333 long-stay mentally ill patients.

| Markers               | No. | %    | CI 95%  |
|-----------------------|-----|------|---------|
| **Infection markers** |     |      |         |
| HBsAg                 | 02  | 0.6  | 0.1–2.4 |
| Anti-HBc              | 14  | 4.2  | 2.4–7.1 |
| Anti-HBc/ HBsAg       | 01  | 0.3  | 0.0–1.9 |
| Anti-HBc/anti-HBs     | 26  | 7.8  | 5.2–11.3|
| **Immunity marker**   |     |      |         |
| Anti-HBs*             | 14  | 4.2  | 2.4–7.1 |
| **Susceptibility**    |     |      |         |
| Negative for all markers | 276 | 82.9 | 78.3–86.6|

* From a total of 14 anti-HBs-positive patients, 10 had evidence of previous vaccination against HBV.

Discussion

The participants of the study were diagnosed as mentally ill, associated or not to a physical disorder. Mentally inpatients are at risk for HBV infection due to the special behavior that they present. These individuals may share personal hygiene objects, such as toothbrushes and raisers. They may also behave aggressively, which could potentially result in minor abrasions or even lesions. Some are immune compromised in addition to their mental problem. Furthermore, institutionalization may also increase the risk of HBV transmission that appears to be mediated by both prolonged contact between inpatients and behavior due to mental and physical disabilities.

A rate of 12.9% for HBV infection was observed in this study population by serological methods. These data corroborate other studies, although higher rates have been found in previously published studies. Our data also revealed a 9.2% (5/54) rate of OBI, reinforcing the notion that HBV infection is underestimated when HBV DNA is not tested in cases...

Fig. 1 – Phylogenetic-tree of a partial region of pre-S/S2 region of HBV genome, with reference samples (GenBank) of all HBV genotypes and six isolates from the long-stay mentally ill patients from Brazil (represented in boldface). Bootstrap values (2000 replicates) are shown at the branch nodes; values lower than 80% are not shown.
in whom the infection is assumed to be resolved (HBsAg negative, anti-HBc and/or anti-HBs positive cases).

The prevalence of OBI varies according to geographical regions as well as distinct populations. The OBI profile has been reported in different regions around the world with rates ranging from 0% to 50% in healthy patients and blood donors.\(^3\)\(^3\)\(^5\)\(^3\) It has also been reported in 30–95% of at-risk individuals such as chronic hepatitis C patients.\(^3\)\(^6\)\(^7\)

Considering the OBI data in mentally ill inpatient population, only one study was conducted with similar population in Brazil, which detected HBV-DNA in 13.4% of HBsAg negative samples.\(^1\)

Among inpatients with OBI it is possible to observe differences in the serum anti-HBc and/or anti-HBs markers are present, however about 20% of patients are negative for both markers.\(^6\) In this study, only positive patients for HBV markers were tested for HBV DNA, therefore the rate of OBI could have been underestimated.

Although the anti-HBc/anti-HBs profile is indicative of viral clearance and immunity, when in association with viral DNA positivity it is considered a case of persistent infection.\(^11\)\(^12\) On the other hand, presence of anti-HBs does not always mean protection against HBV infection, considering the circulation of HBV mutants, for which the anti-HBs antibodies elicited by the HBV vaccine may not be able to exert their neutralizing activity. This fact could explain the occurrence of HBV infection in vaccinated individuals,\(^13\) as observed in one inpatient, who was positive for anti-HBs and HBV DNA (Fig. 1 – accession number KJ434164).

Of the patients, only 4.2% were positive for anti-HBs alone (immunity marker), and 82.9% were susceptible to infection. The number of infected individuals (HBsAg and/or DNA positive) highlights the facilitation of the virus transmission in the institution.

The HBV-DNA positive samples were characterized as genotype A (Fig. 1). This genotype has a global distribution and in Brazil it is the most prevalent, followed by genotypes D and F.\(^4\)\(^4\)\(^4\)\(^7\) It has been suggested that acute infection with HBV genotype A may increase the risk of progression to chronic disease.\(^4\)\(^8\)\(^4\)\(^9\) Despite the risk factor associated with HBV transmission that the patients may present, the phylogenetic analysis carried out with DNA sequences of six samples showed that they were not identical, indicating no HBV transmission among these patients.

Finally, studies on HBV prevalence that use methodologies that allow for the identification of serological profiles as well as the presence of viral DNA are essential for identifying infected people in order to minimize complications arising from HBV infection and also to help decreasing viral dissemination.

The presence of occult infection among long-stay mentally ill patients is worrying considering not only the possibility of progression to cirrhosis and carcinoma but also because it may cause viral transmission, due to the living conditions of the individuals. Therefore our data underscores the need for periodic monitoring of inpatients for the possibility of viral transmission and reinforce the importance of the adoption of preventive vaccination against HBV of inpatients and staff.

### Funding

This study was supported by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq – Brazil) process number 481059/2010-5.

### Conflicts of interest

The authors declare no conflicts of interest.

### Acknowledgment

The authors wish to thank CNPq for financial support.

### References

1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30: 2212–9.
2. World Health Organization. Hepatitis B. http://www.who.int/mediacentre/factsheets/fs204/en/ [accessed 19.01.15].
3. Elgouhari HM, Tamimi TIA, Carey WD. Hepatitis B virus infection: understanding its epidemiology, course, and diagnosis. Clevecl Clin J Med. 2008;75(12):881–9.
4. Carey WD. The prevalence and natural history of hepatitis B in the 21st century. Clevecl Clin J Med. 2009;76:2–5.
5. Raimondo G, Allain JP, Brunetto MR, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008;49:652–7.
6. Cheng HR, Kao JH, Wu HL, et al. Clinical and virological features of occult hepatitis B in patients with HBsAg seroclearance post-treatment or spontaneously. Liver Int. 2014;34:e71–9.
7. Kwak MS, Kim YJ. Occult hepatitis B virus infection. World J Hepatol. 2014;6(12):860–9.
8. Kang SY, Kim MH, Lee WI. The prevalence of “Anti-HBc Alone” and HBV DNA detection among Anti-HBc alone in Korea. J Med Virol. 2010;82:1508–14.
9. Rios-Ocampo WA, Cortes-Mancera F, Olarte JC, Soto A, Navas MC. Occult hepatitis B virus infection among blood donors in Colombia. Virol J. 2014;11:206.
10. Franz C, Perez Rde M, Zalis MG, et al. Prevalence of occult hepatitis B virus infection in kidney transplant recipients. Mem Inst Oswaldo Cruz. 2013;108(5):657–60.
11. Attia KA, Eholié S, Messou E, et al. Prevalence and virological profiles of hepatitis B infection in human immunodeficiency virus patients. World J Hepatol. 2012;4(7):218–23.
12. Sawayama Y, Hayashi J, Kakuda K, et al. Hepatitis C virus infection in institutionalized psychiatric patients. Dig Dis Sci. 2000;45(2):351–6.
13. Campos LN, Guimarães MD, Carmo RA, et al. HIV, syphilis, and hepatitis B and C prevalence among patients with mental illness: a review of the literature. Cad Saúde Pública. 2008;24(4):S607–20.
14. Souza MM, Barbosa MA, Tavares ANB, Daher RR, Martins RMB, Cardoso DDP. Soroprevalência da infeção pelo virus da hepatitis B em portadores de doença mental. Rev Bras Psiquiatr. 2004;16:35–45.
15. Esquivel CA, Valenzuela MAA, Suárez MFM, Andrade FE. Hepatitis B virus infection among inpatients of a psychiatric hospital of Mexico. Clin Pract Epidemiol Mental Health. 2005;1:10.
16. Guimarães MDC, Campos LN, Melo APS, Carmo RA, Machado CJ, Acurcio FA. Prevalence of HIV, syphilis, hepatitis B and C among adults with mental illness: a multicenter study in Brazil. Rev Bras Psiquiatr. 2009;31(1):43–7.

17. Jasuja S, Thompson ND, Peters PJ, et al. Investigation of hepatitis B virus and human immunodeficiency virus transmission among severely mentally ill residents at a long term care facility. PLoS ONE. 2012;7(8):e43252.

18. Carmo RA, Melo AP, Dezanet LN, de Oliveira HN, Cournos F, Guimarães MD. Correlates of hepatitis B among patients with mental illness in Brazil. Gen Hosp Psychiatry. 2014;36(4):398–405.

19. Durotoyte IA, Issa BA, Fadeye A, et al. Sero-prevalence of hepatitis B and C among mentally ill patients attending a tertiary hospital in Nigeria. Ann Afr Med. 2014;13(4):210–6.

20. Niel C, Moraes MT, Gaspar SM, Yoshida CF, Gomes AS. Genetic diversity of hepatitis B virus strains isolated in Rio de Janeiro, Brazil. J Med Virol. 1994;44(2):180–6.

21. Motta-Castro ARC, Martins RMB, Yoshida GFT, et al. Hepatitis B virus infection in isolated Afro-Brazilian communities. J Med Virol. 2005;77:188–93.

22. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. PNAS. 1977;74:5463–7.

23. Ewing B, Hillier L, Wendl MC, Green P. Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome Res. 1998;8:175–85.

24. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG. The CLUSTAL_X Windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 1997;25(24):4876–82.

25. Saitou N, Nei M. The Neighbor-Joining Method – a new method for reconstructing phylogenetic trees. Mol Biol Evol. 1987;4:406–25.

26. Kimura M. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequence. J Mol Evol. 1980;16(2):111–20.

27. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGAS: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol. 2011;28(10):2731–9.

28. Asensio F, Bayas JM, Bertran MJ, Asenjo MA. Prevalence of hepatitis B infection in long-stay mentally handicapped adults. Eur J Epidemiol. 2000;16(8):725–9.

29. Vellinga A, Van Damme P, Meheus A. Hepatitis B and C in institutions for individuals with intellectual disability. J Intellect Disabil Res. 1999;43:445–53.

30. Cramp ME, Grundy HC, Perinpanayagam RM, Barnado DE. Seroprevalence of hepatitis B and C virus in two institutions caring for mentally handicapped adults. J R Soc Med. 1996;89:401–2.

31. Almeida RC, Pedroso ERF. Vulnerabilidade e exposição a marcadores sorológicos dos vírus da imunodeficiência humana, hepatites B e C, vírus linfotrópico de células T humanas e sífilis em pacientes psiquiátricos internados em hospital público. Rev Med Minas Gerais. 2004;14:244–50.

32. Pirl WF, Greer JA, Weissgarber C, Liverant G, Safren SA. Screening for infectious diseases among patients in a state psychiatric hospital. Psychiatr Serv. 2005;56(12):1614–6.

33. Wolff FH, Fuchs SC, Brandao ABM. Absence of occult hepatitis B among blood donors in southern Brazil. Braz J Infect Dis. 2011;15(2):159–62.

34. Vazeejali M, Rashidpour S, Rezaee H, et al. Hepatitis B viral DNA among HBs antigen negative healthy blood donors. Hepat Mon. 2013;13(3):e6590.

35. Villar LM, Amado AL, Almeida AJ, Paula VS, Lewis-Ximenez LL, Lampe E. Low prevalence of hepatitis B and C virus markers among children and adolescents. Biomed Res Int. 2014;1:1–5.

36. Koike K, Kobayashi M, Gondo M, et al. virus DNA is frequently found in liver biopsy samples from hepatitis C virus-infected chronic hepatitis patients. J Med Virol. 1998;54:249–55.

37. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med. 1999;341:22–6.

38. Ocana S, Cassas ML, Buhigas I, Lledo JL. Diagnostic strategy for occult hepatitis B virus infection. World J Gastroenterol. 2011;17(12):1553–7.

39. Candotti D, Lin CK, Belkhiri D, et al. Occult hepatitis B infection in blood donors from South East Asia: molecular characterisation and potential mechanisms of occurrence. Gut. 2012;61:1744–53.

40. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis. 2002;2(8):479–86.

41. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol. 2005;42:302–8.

42. Romano L, Velati C, Cambiè G, Fomiatti L, Galli C, Zanetti AR. Hepatitis B virus infection among first-time blood donors in Italy: prevalence and correlates between serological patterns and occult infection. Blood Transfus. 2013;23:1–10.

43. Jaramillo CM, Navas MC. Escape mutants of hepatitis B virus. Rev Chilena Infectol. 2015;32(2):190–7.

44. Matos MA, Reis NR, Kozlowski AG, et al. Epidemiological study of hepatitis A, B and C in the largest Afro-Brazilian isolated community. Trans R Soc Trop Med Hyg. 2009;103(9):899–905.

45. Santos AO, Alvarado-Mora MV, Botelho L, et al. Characterization of hepatitis B virus (HBV) genotypes in patients from Rondônia, Brazil. Virol J. 2010;7:315.

46. Barros LAS, Pessoni GC, Telles SA, et al. Epidemiology of the viral hepatitis B and C in female prisoners of metropolitan regional prison complex in the state of Goiás, Central Brazil. Rev Soc Bras Med Trop. 2013;46(1):24–9.

47. Crispim MA, Fraiji NA, Campello SC, Schriefer NA, Stefani MM, Kiesslich D. Molecular epidemiology of hepatitis B and hepatitis delta viruses circulating in the Western Amazon region, North Brazil. BMC Infect Dis. 2014;14:94.

48. Mayerat C, Mantegani A, Frei PC. Does hepatitis B virus (HBV) genotype influence the clinical outcome of HBV infection? J Viral Hepat. 1999;6(4):299–304.

49. Suzuki Y, Kobayashi M, Ikeda K, et al. Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan. J Med Virol. 2005;76:33–9.